RAC1 and cancer: Park et al. (2019) identified the small molecule aurintricarboxylic acid through a surface plasmon resonance screening as a compound that binds to Fgd5, thus inactivating Rac1 with an IC50 of 157 nM. Further studies are needed to validate these results in vivo and to delineate the utility of targeting Fgd5 to block cancer progression.